Objectives To assess the association between biomarkers of thyroid status and 5a-stanols in patients with sitosterolemia treated with ezetimibe (EZE).
Results EZE increased FT3/FT4 (10% ± 4%; P = .02). EZE reduced plasma and red blood cells sitostanol (−38% ± 6% and −20% ± 4%; all P < .05) and cholestanol (−18% ± 6% and −13% ± 3%; all P < .05). The change in plasma cholestanol level on EZE inversely correlated with the change in FT3/FT4 (r = −0.86; P = .01). EZE lowered total cholesterol (P < .0001) and did not affect 7a-hydroxy-4-cholesten-3-one cholestanol. EZE increased (P < .0001) lathosterol initially, but the level was not sustained, resulting in similar levels at week 14 off EZE and on EZE.
Conclusion
In patients with STSL, 5a-stanols levels might be associated with thyroid function. EZE reduces circulating 5a-stanols while increasing FT3/FT4, implying increased conversion of T4 to T3, thus possibly improving thyroid hormone status. (J Pediatr 2017; 188:198-204 ).
Trial registration ClinicalTrials.gov NCT01584206.
S itosterolemia (STSL) is a rare disease caused by mutations in either of the adenosine triphosphate-binding cassette transporter genes, ABCG5 or ABCG8, that result in accumulation of plant sterols and their corresponding saturated 5a-stanols in the body. 1, 2 Clinical features of STSL include xanthomas, premature atherosclerosis, and macrothrombocytopenia. 1 Endocrine disruption has also been reported. 3 Synthesis of thyroid hormones seem to be deranged in cerebrotendinous xanthomatosis (CTX), a disorder of bile acid synthesis, [4] [5] [6] and STSL. 7 Both disorders have elevated plasma and tissue cholestanol levels that might contribute to thyroid imbalance. Specifically, concurrent high levels of cholestanol, a 5a-stanol-saturated derivative of cholesterol, 8 and hypothyroidism have been observed in CTX [4] [5] [6] and STSL, 7 suggesting a link between underactive thyroid and 5a-stanols. However, the association between thyroid function and 5a-stanols has not, to our knowledge, been elucidated further.
For most individuals on a typical Western diet, 5a-stanols (cholestanol and sitostanol) are almost absent from the diet; thus, their presence in the body is mostly via endogenous production from cholesterol and sitosterol, respectively. [9] [10] [11] Cholestanol is biosynthesized from cholesterol 12, 13 or its metabolite 7a-hydroxy-4-cholesten-3-one (7a-H-C4), which is also involved in bile acid synthesis. 14, 15 Plasma cholestanol levels are normally low, but high in STSL 16 and CTX. 17 Biosynthesis of cholestanol precursors, including 7a-H-C4 and cholesterol (reflected by its synthesis marker lathosterol), are low in STSL, [18] [19] [20] so it is unclear if cholestanol accumulation arises from the diet or endogenously. Ezetimibe (EZE), the primary treatment for STSL that works by reducing plant sterol absorption, reduces intestinal sterol uptake, 21, 22 but its effect on circulating 5a-stanols has not yet been examined. This study aimed to explore the nature of the relationship 7a-H-C4 7a-Hydroxy-4-cholesten-3-one C4-d7 between 5a-stanols and thyroid hormones and to determine the effects of EZE on thyroid hormones as well as blood levels of sitostanol, and cholestanol and its precursors (total cholesterol [TC] and its synthesis marker lathosterol, and 7a-H-C4) in patients with STSL.
Methods
The study design from which these data were taken has been reported previously. 23 This report was part of a much larger pilot, interventional trial (ClinicalTrials.gov: NCT01584206) investigating the effect of EZE on sterol metabolism in patients with STSL. In summary, 8 patients (5 males and 3 females, between 16 and 56 years of age) with homozygous ABCG8 S107X mutation (NM_022437.2:c.320C>G) were recruited from Hutterite communities. The study was approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the University of Manitoba Biomedical Ethics board, and written informed consent was obtained from all patients. After enrollment, patients were taken off their EZE treatment for 14 weeks (off EZE). For the full study design, blood was collected at weeks 2, 4, 6, 8, 10, 12, and 14. After 14 weeks off EZE, patients were instructed to take EZE (10 mg/ day) for 14 weeks (on EZE). Blood was collected following the same schedule as in the off EZE phase. Only selected samples from the blood collection protocol were used for assessment of thyroid hormones (see below) owing to the limited availability of serum samples required. Serum, plasma, and red blood cells (RBC) fractions were separated by centrifugation at 3000 rpm for 20 minutes at 4°C, and stored at −80°C until analysis.
The concentrations of serum thyroid hormones were as follows: free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured at baseline (beginning of the off EZE phase), and 8 and 14 weeks off EZE and on EZE by an outsourced laboratory (GammaDynacare Medical Laboratories, Winnipeg, Manitoba, Canada) using automated immunoassays (Abbott Laboratories, Abbott Park, Illinois). The coefficient of variation (CV) for the assays were as follows: FT4, intra-CV <2.2% and inter-CV <4.9%; FT3, intra-CV <3.2% and inter-CV <5.9%; and TSH, intra-CV <1.2% and inter-CV <2.8%. The ratio of FT3 to FT4 (FT3/ FT4) was calculated as an indirect index of deiodinase activity. 24 Plasma and RBC 5a-stanols, and TC and lathosterol levels were measured using gas-liquid chromatography equipped with a flame ionization detector (Varian 430-GC; Agilent Technologies, Santa Clara, California) as published previously. 23 Measurement of RBC sterol levels indicates a longer term average of plasma levels and a better reflection of tissue stores. Plasma sterol and 5a-stanol levels were determined at baseline and biweekly up to 14 weeks off EZE and on EZE, whereas those in RBC were measured at baseline, 4, 8, 10, and 14 weeks off EZE and on EZE.
Serum 7a-H-C4 levels were measured at baseline, 4, 8, 10, and 14 weeks off EZE and on EZE using ultraperformance liquid chromatography tandem mass spectrometry. 25 Serum (50 µL) was diluted with 100 µL of double distilled water (ddH 2O), and 50 µL of the 40 ng/mL deuterated internal standard 7-hydroxy-4-cholesten-3-one-25,26,26,26,27,27,27-d7 (C4-d7) (Avanti Polar Lipids Inc, Alabaster, Alabama) and 0.2 mL of methanol were added. The mixture was applied to a Bond Elut C18 cartridge (Agilent Technologies Inc, Mississauga, Ontario, Canada) preconditioned with 2 mL methanol followed by 2 mL ddH2O. The cartridge was washed twice with 2 mL ddH2O and 2 mL of methanol. After evaporation, the residue was dissolved in 80 µL methanol and 3 µL was injected into the system. The separation was performed using a Kinetix XB-C18 column (2.1 × 100 mm, particle size 1.7 µm; Phenomenex, Torrance, California) at 35°C. The mobile phases were A (0.1% formic acid in ddH2O) and B (0.1% formic acid in acetonitrile) and used at a flow rate of 0.20 mL/minute. The gradient program was started at 10% phase A and 90% phase B for 6 minutes, increased linearly to 100% phase B for 4 minutes, held at 100% phase B for 4 minutes, then returned to initial conditions and re-equilibrated for 4 minutes. The total run time for each sample analysis was 16 minutes. The quantitative data were acquired using multireaction monitoring mode. The multireaction monitoring transitions for 7a-H-C4 were 401.4 > 383.4 m/z and for C4-d7 were 408.4 > 390.4 m/ z. The following settings were applied during each run: capillary voltage 3.50 kV; source temperature 100°C; desolvation temperature 400°C; nitrogen gas with flow rates of desolvation and cone gas of 400 and 50 L/hour, respectively; argon was used as the collision gas; cone voltage was 20V; and collision energy was 20 eV.
Statistical Analyses
Statistical analyses were performed using SPSS 21.0 (SPSS, Inc, Chicago, Illinois). All data are presented as mean ± SEM. Statistical significance was set at P < .05. Linear mixed-model analysis was used where treatment and time were specified as fixed factors, and age and body weight were specified as a covariate in the model. Significant treatment effects were examined with Bonferroni adjustment for multiple comparisons. Both treatment and time (with time representing the different time periods) were entered into the model. When a significant treatment effect, but no significant treatment-by-time interaction, was observed, the interpretation was that the treatment effect was consistent over the different time periods. Relationships between 2 variables were assessed with stepwise multiple linear regression analysis. Percentage change from baseline for each phase was analyzed using 2-tailed paired Student t test. Data that were not normally distributed, as determined by a Shapiro-Wilk test, were log or inverse transformed before statistical analysis.
Results
Baseline characteristics of the study patients are presented in Table I . All patients were euthyroid based on serum TSH. Mean FT3 concentration was at the lower limit of the normal range (0.3-0.7 ng/dL) with 1 patient at 0.4 ng/dL, 5 patients at 0.3 ng/ dL, and 1 having a subnormal level of 0.2 ng/dL. Mean serum FT4 concentration was within the normal range (0.7-1.8 ng/ Volume 188 • September 2017 dL), although 2 patients were near the lower limit of normal (0.7-0.9 ng/dL). The serum FT3/FT4 range was within the reference range reported in euthyroid adults (0.27-0.37). 26 All patients had high plasma and RBC cholestanol and sitostanol levels. Plasma and RBC levels of cholestanol were similar (P = .20), whereas sitostanol tended to be higher in plasma than in RBC (P = .07). Lathosterol and its ratio to TC were higher (P < .05) in RBC relative to plasma. The mean serum 7a-H-C4 concentration was 16 ± 4 ng/mL; the normal range of 7a-H-C4 has not been established. Two subjects had Achilles tendon xanthomas, which regressed with EZE (data not shown). Assessment of the subjects by their physicians before enrollment in the study was carried out using noninvasive imaging to exclude coronary and carotid plaque, and found no evidence of atherosclerotic manifestations (ie, heart murmurs and vascular bruits) in all 8 subjects. There were no cases of myocardial infarction, atrial fibrillation, diabetes, heart failure, hypertension, stroke, or any other comorbidity among the 8 patients.
Serum FT3 concentrations did not change over time (P = .56), but were higher generally on EZE than off EZE (Figure 1 , A, Table II; Table II available at www.jpeds.com). At week 8 off EZE, serum FT3 levels tended to decrease (−10%; 0.27 ± 0.02 ng/dL vs 0.30 ± 0.02 ng/dL; P = .08) compared with baseline. Although the decrease in FT3 level was evident in 5 patients (−23.0 ± 6.0%), 1 patient had no change, and the remaining 2 patients had an increase of 16 ± 1.0% compared with baseline. At week 14, the same 5 patients had an average decrease of 25 ± 6.0% in FT3 levels compared with baseline, but the remaining three patients had an increase of 22 ± 5.0%; therefore, on average the change in FT3 from baseline at week 14 off EZE was not significant (P = .18) (Table III; available at www.jpeds.com). At week 14 off EZE, the percentage changes in FT3 from baseline negatively correlated with the percentage changes in RBC cholestanol from baseline (r = −0.74; P = .04), but not with plasma cholestanol (r = −0.36; P = .38), suggesting that increases in cholestanol levels may contribute to decrease in FT3 observed during the off EZE phase. In contrast, on EZE FT3 concentrations were about 13% higher at week 8 compared with week 8 off EZE (P = .04), whereas at week 14 the difference was no longer significant (0.31 ± 0.02 ng/dL vs 0.28 ± 0.02 ng/dL; P = .07) (Figure 1, A) .
Serum FT4 concentrations did not change over 14 weeks of treatment with EZE (P = .50; Table II) , and were similar (P = .24) between off EZE and on EZE (Figure 1, B) . Likewise, off EZE FT4 levels did not change either at week 8 or 14 compared with baseline (Table III) . Serum FT3/FT4 did not change over time (P = .17), but was higher on average on EZE than off EZE (P = .001; Table II ). At 8 and 14 weeks off EZE, the changes in FT3/FT4 compared with baseline were the same as those of FT3 (Table III) . On EZE, serum FT3/FT4 was higher (10 ± 4%; P = .02) at week 8 compared with week 8 off EZE and remained high at week 14 (0.32 ± 0.03 vs 0.29 ± 0.02; P = .02) (Figure 1, C) . Serum TSH concentrations did not change over time (P = .42), but were higher on average on EZE than off EZE (P = .008; Table II ). TSH levels did not change at weeks 8 and 14 off EZE compared with baseline (Table III) . Percentage changes in TSH at week 14 off EZE from baseline negatively correlated with those in plasma cholestanol (r = −0.81; P = .02), sitostanol (r = −0.82; P = .01), and TC (r = −0.65; P = .08). Likewise, off EZE TSH levels at week 14 negatively correlated with cholestanol concentrations in RBC (r = −0.78; P = .02) but not plasma (r = −0.56; P = .15), suggesting that long-term cholestanol levels may negatively affect TSH levels. In contrast, on EZE TSH concentrations were 2-fold higher at week 8 compared with week 8 off EZE (4.0 ± 0.8 mU/L vs 2.6 ± 0.4 mU/L; P = .008), but the difference was not significant at week 14 (P = .09) (Figure 1, D) . Moreover, correlations between TSH and cholestanol levels in plasma (r = −0.26; P = .54) and RBC (r = −0.64; P = .10) were insignificant by 14 week on EZE.
EZE lowered plasma (P = .002) and RBC (P < .0001) sitostanol concentrations over 14 weeks (Table II) with substantial decreases (38 ± 6% and 21 ± 2%; P < .0001) noted at week 14 compared with off EZE (Figure 2, A and B) . These decreases (28 ± 7% and 21 ± 2%; all P < .0001) were sustained over time when on EZE plasma and RBC sitostanol concentrations at week 14 were adjusted for TC (P = .005 and P = .07, respectively) ( Table II) . EZE time-dependently lowered plasma cholestanol concentrations (P < .0001) ( Table II) , and largely decreased cholestanol at week 6 (40 ± 3%; P < .0001), but the difference at week 14 was only 18 ± 6% (P = .001) compared with off EZE (Figure 2, C) . When adjusted for TC, plasma cholestanol changed over time (P = .005) ( Table II) with lower on EZE concentrations (6 ± 2%; P = .05) noted at week 14. EZE time-independently lowered RBC cholestanol concentrations (Table II) , with a decrease of 13% (P < .0001) noted at week 14 (Figure 2, D) and when adjusted for TC (P = .006).
EZE time-dependently lowered plasma TC concentrations (P < .0001) ( Table II) . EZE substantially decreased (37%; P < .001) TC at week 6 compared with off EZE; however, at week 14 the difference was only 12% (P = .01) (Figure 2, E) . EZE-induced changes in plasma TC strongly correlated (r = 0.94; P = .001) with those in plasma cholestanol. RBC TC concentrations changed over time (P = .01) ( Table II) . However, on EZE, the RBC TC levels were decreased (13 ± 1.0%; P < .0001) at week 4 but were similar (P = 1.0) to off EZE at week 14 (Figure 2, F) . EZE time-dependently increased plasma lathosterol (Table II) with increases of 84% (P = .004) noted at week 12; however, at week 14 the difference was not significant compared with off EZE (P = .91) (Figure 3, A) . Similar results were observed when lathosterol levels were adjusted for TC (Table II) . EZE increased RBC lathosterol concentrations but the effect was not time dependent (Table II) , suggesting a consistent effect of EZE on cholesterol synthesis in RBC. EZE increased (P < .01) RBC lathosterol 2-fold levels at week 4, but at week 14 they were comparable (P = .12) with off EZE (Figure 3, B) . Similar results were observed in TC-adjusted RBC lathosterol (Table II) . EZE did not affect absolute and TCadjusted serum 7a-H-C4 levels (Table II and Figure 3 , C). Changes in serum 7a-H-C4 after EZE did not correlate (r = −.02; P = .97) with those in plasma cholestanol. At week 14 off EZE, both plasma and RBC cholestanol levels inversely correlated with FT3 and FT3/FT4. Conversely, only plasma sitostanol levels significantly inversely correlated with FT3 and FT3/FT4. Likewise, only EZE-induced changes in plasma cholestanol significantly inversely correlated with those in FT3/FT4 while those in sitostanol did not attain significance (Table IV ; available at www.jpeds.com).
Discussion
STSL is an autosomal recessive disorder caused by mutation in the ABCG5 or ABCG8 genes, and characterized by increased plasma and tissue levels of plant sterols and 5a-stanols. 1, 2 These compounds have been shown to disrupt the endocrine system in mice with STSL, 27 although in humans endocrine insufficiency has only been reported once. 3 Plasma cholestanol, a 5a-stanol, is generally low in healthy subjects (<0.4 mg/dL) 16 but high in STSL (0.5-2.0 mg/dL) 16 and CTX (1-4 mg/dL), a disorder of bile acid synthesis caused by mutations in CYP27A1 gene that codes for sterol 27-hydroxylase, an essential enzyme for bile acids synthesis. 17 Increased cholestanol levels in CTX have been associated with hypothyroidism. 4 The current results are in accordance with previous reports, 11, 19 showing increased plasma and RBC sitostanol and cholestanol levels in STSL. These levels were increased by ≥30% when EZE was discontinued, and inversely correlated with serum FT3 and FT3/FT4, suggesting that 5a-stanols may modulate thyroid function. It is possible that, when the patients were taken off EZE, the accumulation of cholesterol, plant sterols, and 5a-stanols increased in the blood and tissues, which may induce inflammation, and in turn may influence deiodination of T4 to T3 and cause the low FT3 levels observed at weeks 8 and 14 off EZE. Cytokines have been shown to inhibit sodium iodide transporter mRNA expression and iodide uptake activity in human and rat thyroid cells 28 and alter serum thyroid hormone levels directly or indirectly by impairing the hypothalamicpituitary-thyroid axis, 29 reducing the activity or release of TSH, 30, 31 inhibiting the synthesis or conversion of thyroid hormones and regulating their protein binding. 29, 32 EZE, the primary treatment for STSL, reduces intestinal uptake of sterols by inhibiting the transport function of Niemann-Pick C 1-like 1 protein. 21, 22 EZE has no effect on thyroid hormone levels in healthy subjects, 33, 34 where the plasma 5a-stanols are low. The current patients were on average euthyroid, although baseline serum FT3 concentrations were within the lower levels of the reference range for 6 patients, and 1 patient had subnormal level of 0.2 ng/dL. FT4 levels were near the lower limit of normal in 2 patients. In the current study, EZE did not change serum thyroid hormones significantly, but increased serum FT3/FT4, reflecting increased peripheral conversion of the less metabolically potent T4 to the stronger T3, which is catalyzed by 5′-deiodinase. Increased FT3/FT4 with EZE suggests increased 5′-deiodinase activity to provide sufficient T3 and maintain euthyroidism.
TSH is important for the conversion of T4 to FT3, and its release is under negative feedback regulation by thyroid hormone at the pituitary and hypothalamic levels. An approximately 25% increase in serum TSH was reported after 4 weeks of EZE compared with baseline in high cardiovascular risk subjects. 35 In the current study, EZE increased FT3 and TSH at week 8 and then levels returned to similar levels at week 14 on EZE, whereas the FT3/FT4 ratio at week 14 remained high. The mechanism mediating the increased TSH concentrations in response to EZE is not clear. A and B, Plasma and RBC sitostanol, C and D, plasma and RBC cholestanol, and E and F, plasma and RBC TC levels in patients with STSL (n = 8) throughout 14 weeks off EZE (OFF EZE) and on EZE (ON EZE). Data are mean ± SEM. *P < .05, **P < .01, ***P < .0001 vs OFF EZE. †P < .05 vs baseline.
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The current results fit well with the studies outside of STSL, reporting reduced peripheral conversion of T4 to T3 and circulating T3 levels in hepatic cirrhosis patients, 36, 37 where the serum 5a-stanols and plant sterols levels were increased owing to impaired biliary elimination. [38] [39] [40] In addition, we observed substantial decreases in plasma cholestanol levels with EZE at week 6, suggesting reduced intestinal absorption of cholestanol and its precursors. However, the levels increased during the last 4 weeks of the phase, and only a 20% decrease in cholestanol was noted at week 14. This finding suggests increases in precursor availability for synthesis of cholestanol, which potentially would attenuate decreases in plasma cholestanol. In contrast, decreases in RBC cholestanol levels were consistent over time, owing to the slower incorporation rate of cholestanol from plasma into RBC membrane, because RBC do not make cholestanol. 41 Unlike cholestanol, decreases in plasma and RBC sitostanol levels with EZE were progressive over 14 weeks, suggesting that time may be required for further reducing sitostanol levels.
The results of this study showed evidence for altered thyroid hormone metabolism in STSL. An inverse relationship between plasma 5a-stanols levels and FT3/FT4 in STSL was demonstrated. EZE, the treatment for STSL, seems to be as effective in reducing 5a-stanol concentrations in STSL as in hypercholesterolemia. EZE reduces blood levels of sitostanol and cholestenol, as well as their ratios to TC, while increasing serum FT3/FT4, thereby potentially enhancing peripheral conversion of T4 to T3, and reducing the risk of the development of hypothyroidism in patients with STSL. Further studies are needed to elucidate a potential direct action of 5a-stanols on the T4-to-T3 deiodination process in peripheral tissues. ■ Figure 3 . A and B, Plasma and RBC lathosterol levels and C, serum 7a-H-C4 in patients with STSL (n = 8) throughout 14 weeks off EZE (OFF EZE) and on EZE (ON EZE). Data are mean ± SEM. *P < .05, **P < .01, ***P < .0001 vs OFF EZE. †P < .05 vs baseline. 
